NCT05470725 is a Phase 1 clinical trial of CIN-107 in Hypertension, sponsored by AstraZeneca.

Who is sponsoring NCT05470725?

NCT05470725 is sponsored by AstraZeneca.

What drugs are being tested in NCT05470725?

Interventions in NCT05470725: CIN-107.

What condition does NCT05470725 study?

NCT05470725 studies Hypertension.

Is NCT05470725 still recruiting?

NCT05470725 is currently completed. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05470725

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function

Completed Phase 1 Last updated 14 August 2023

What this trial tests

Phase 1 trial testing CIN-107 in Hypertension in 33 participants. Completed in 30 April 2021.

Timeline

12 January 2021

Primary endpoint
30 April 2021

30 April 2021

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	12 January 2021
Primary completion	30 April 2021
Estimated completion	30 April 2021
Sites	2 locations across United States

Drugs / interventions tested

CIN-107 — full drug profile →

Conditions studied

Hypertension — all drugs for Hypertension →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 80, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights - A Systematic Review.
Cicero AFG, Tocci G, Avagimyan A, Penson P, et al · · 2025 · cited 7× · PMID 40885884 · DOI 10.1007/s40265-025-02229-2

Verify or expand the search:

Other trials of CIN-107

Trials testing the same drug.

NCT05432167 — A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease · Phase 2 · completed
NCT05459688 — Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 · Phase 2 · completed
NCT05137002 — A Study of CIN-107 in Patients With Uncontrolled Hypertension · Phase 2 · completed
NCT05526690 — Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy Subjects · Phase 1 · completed
NCT04519658 — A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) · Phase 2 · completed

Other recruiting trials for Hypertension

Currently open trials in the same condition.

NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A · NA · recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S · recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia · Phase 2 · recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension · NA · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05470725 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05470725.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing